RLAY vs. ARQT, TARS, HRMY, TVTX, JANX, IRON, AGIO, APGE, MESO, and VERA
Should you be buying Relay Therapeutics stock or one of its competitors? The main competitors of Relay Therapeutics include Arcutis Biotherapeutics (ARQT), Tarsus Pharmaceuticals (TARS), Harmony Biosciences (HRMY), Travere Therapeutics (TVTX), Janux Therapeutics (JANX), Disc Medicine (IRON), Agios Pharmaceuticals (AGIO), Apogee Therapeutics (APGE), Mesoblast (MESO), and Vera Therapeutics (VERA). These companies are all part of the "pharmaceutical products" industry.
Relay Therapeutics vs.
Arcutis Biotherapeutics (NASDAQ:ARQT) and Relay Therapeutics (NASDAQ:RLAY) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, community ranking, media sentiment and profitability.
Relay Therapeutics has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -140.97%. Relay Therapeutics' return on equity of -45.75% beat Arcutis Biotherapeutics' return on equity.
Arcutis Biotherapeutics has higher revenue and earnings than Relay Therapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks.
Arcutis Biotherapeutics has a beta of 1.48, suggesting that its stock price is 48% more volatile than the S&P 500. Comparatively, Relay Therapeutics has a beta of 1.65, suggesting that its stock price is 65% more volatile than the S&P 500.
Arcutis Biotherapeutics received 6 more outperform votes than Relay Therapeutics when rated by MarketBeat users. However, 70.45% of users gave Relay Therapeutics an outperform vote while only 66.67% of users gave Arcutis Biotherapeutics an outperform vote.
Arcutis Biotherapeutics currently has a consensus target price of $18.80, indicating a potential upside of 19.52%. Relay Therapeutics has a consensus target price of $19.80, indicating a potential upside of 627.94%. Given Relay Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Relay Therapeutics is more favorable than Arcutis Biotherapeutics.
In the previous week, Arcutis Biotherapeutics had 5 more articles in the media than Relay Therapeutics. MarketBeat recorded 10 mentions for Arcutis Biotherapeutics and 5 mentions for Relay Therapeutics. Arcutis Biotherapeutics' average media sentiment score of 1.13 beat Relay Therapeutics' score of 0.83 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media.
97.0% of Relay Therapeutics shares are owned by institutional investors. 9.5% of Arcutis Biotherapeutics shares are owned by company insiders. Comparatively, 4.3% of Relay Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Relay Therapeutics beats Arcutis Biotherapeutics on 11 of the 18 factors compared between the two stocks.
Get Relay Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RLAY and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Relay Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:RLAY) was last updated on 3/28/2025 by MarketBeat.com Staff
